Focus: Fate Therapeutics is a public biotechnology company focused on stem cell-modulating therapeutics and cell therapy, headquartered in San Diego with a pipeline of 24 clinical programs spanning oncology, hematologic malignancies, and autoimmune indications.
Profile data last refreshed 10h ago · AI intelligence enriched 2mo ago
High technical upside in cell therapy for specialists willing to accept significant financial risk and career uncertainty in a pre-revenue, cash-constrained biotech.
Help build intelligence for Fate Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Fate Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by Analysts - MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by Analysts MarketBeat
Fate Therapeutics Announces Encore Clinical Data - GlobeNewswire
Fate Therapeutics Announces Encore Clinical Data GlobeNewswire
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference - GlobeNewswire
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference GlobeNewswire
BlackRock Inc. Makes New Investment in Fate Therapeutics, Inc. $FATE - MarketBeat
BlackRock Inc. Makes New Investment in Fate Therapeutics, Inc. $FATE MarketBeat
A lupus trial that could support approval is on Fate Therapeutics’ agenda Sept. 9. - Stock Titan
A lupus trial that could support approval is on Fate Therapeutics’ agenda Sept. 9. Stock Titan
574,995 Shares in Fate Therapeutics, Inc. $FATE Acquired by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
574,995 Shares in Fate Therapeutics, Inc. $FATE Acquired by Connor Clark & Lunn Investment Management Ltd. MarketBeat
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo